Search
Spotlight
In-person and virtual events just for HCPs
In-person and virtual events just for HCPs
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
Pipeline Report
OncClub
All Oncology News
Pipeline Report
Media
Insights
Medical World News
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Insights
Medical World News
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
Publications
Oncology Live®
Oncology Fellows
Supplements and Featured Publications
All Publications
Oncology Live®
Oncology Fellows
Supplements and Featured Publications
All Publications
CME/CE
Resources
Interactive Tools
Learning Modules
Sponsored
Interactive Tools
Learning Modules
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
In-person and virtual events just for HCPs
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Daniel J. George, MD, Duke Cancer Center
home
Articles
Future of Treating mRCC
July 23rd 2020
Treating Patients With mRCC Beyond Second-Line
July 23rd 2020
Strategies for Switching From Frontline Therapy to Second-Line Therapy in mRCC
July 23rd 2020
Clinical Trials Shaping Treatment in Relapsed/Refractory mRCC
July 23rd 2020
Choosing Second-Line Therapy in Treatment of mRCC
July 23rd 2020
Tailored Therapy Approaches for Upfront mRCC Treatment
July 23rd 2020
Treating Side Effects of Therapy for mRCC with Steroids
July 23rd 2020
Evaluating Safety Profiles of Upfront Regimens for mRCC
July 23rd 2020
Choosing Upfront Therapy for mRCC
July 23rd 2020
CheckMate 9ER: Phase 3 Trial of Frontline Nivolumab + Cabozantinib
July 23rd 2020
Evaluating Long-Term Follow-Up Data for Treatment of mRCC
July 23rd 2020
Patient Factor Consideration for Treatment of mRCC
July 23rd 2020
Applying Clinical Trial Data for Treatment of mRCC
July 23rd 2020
Clinical Trials Defining the NCCN Guidelines for Frontline Treatment of mRCC
July 23rd 2020
Evaluation of Risk for Frontline Advanced/Metastatic Clear Cell RCC
July 23rd 2020